Text Size
32 studies found for:    "Familial Mediterranean fever"

Modify this search | How to Use Search Results

Show Display Options
RSS Create an RSS feed from your search for:
"Familial Mediterranean fever"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed
Has Results 		Rilonacept for Treatment of Familial Mediterranean Fever (FMF)
Condition: Familial Mediterranean Fever
Interventions: Drug: Rilonacept;   Drug: Placebo
2 Completed Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever
Condition: Familial Mediterranean Fever
Intervention: Drug: Canakinumab
3 Withdrawn Inflammatory Proteins in Familial Mediterranean Fever During Attack and Remission
Condition: Familial Mediterranean Fever
Intervention:
4 Not yet recruiting Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever
Condition: Familial Mediterranean Fever,
Intervention: Drug: Kineret
5 Active, not recruiting Evaluate the Safety and Efficacy of Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever (FMF)
Condition: Colchicine Resistant/Intolerant Familial Mediterranean Fever
Intervention: Drug: Canakinumab
6 Recruiting Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics
Condition: Periodic Disease
Intervention:
7 Completed Pharmacokinetics Study of Colchicine in Familial Mediterranean Fever (FMF) Patients
Condition: Familial Mediterranean Fever
Intervention: Drug: colchicine sprinkle capsules
8 Unknown † Magnetic Resonance (MR) Spectroscopy In Familial Mediterranean Fever (FMF) Patients
Condition: Familial Mediterranean Fever
Intervention:
9 Enrolling by invitation Heat Intolerance in the Group of FMF Patients
Conditions: Familial Mediterranean Fever;   Heat Intolerance;   Heat Tolerance Test
Intervention:
10 Completed Internleukin-1 Trap to Treat Autoinflammatory Disease
Conditions: Inflammation;   Familial Mediterranean Fever;   Still's Disease, Adult-Onset
Intervention: Drug: IL-1 Trap
11 Recruiting Dietary Cholesterol and Defects in Cholesterol Synthesis in Mevalonate Kinase Deficiency
Conditions: Mevalonic Aciduria;   Mevalonate Kinase Deficiency;   Immune System Diseases;   Periodic Fever Syndromes, Hereditary;   Lipid Metabolism, Inborn Errors
Intervention:
12 Active, not recruiting Efficacy and Safety Study of ACZ885 in Patients With Active Recurrent or Chronic (Tumor Necrosis Factor)TNF-receptor Associated Periodic Syndrome (TRAPS)
Condition: TNF-receptor Associated Periodic Syndromes (TRAPS)
Intervention: Biological: ACZ885
13 Recruiting Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)
Condition: DIRA
Intervention: Drug: Rilonacept
14 Terminated Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease
Conditions: NOMID;   CINCA Syndrome
Intervention: Drug: Canakinumab
15 Completed
Has Results 		Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Conditions: Familial Cold Autoinflammatory Syndrome (FCAS);   Familial Cold Urticaria;   Muckle-Wells Syndrome (MWS);   Genetic Diseases, Inborn
Interventions: Drug: rilonacept 160 mg;   Drug: Placebo
16 Completed The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada
Condition: Cryopyrin Associated Periodic Syndrome
Intervention: Drug: canakinumab (company code: ACZ885D)
17 Recruiting Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease
Conditions: Nervous System Malformations;   Arthropathy, Neurogenic;   Urticaria;   Papilledema
Intervention: Drug: Anakinra
18 Recruiting B7 Coreceptor Molecules in Hyper IgD Syndrome Form of Mevalonate Kinase Deficiency
Conditions: Hyper IgD Syndrome;   Mevalonate Kinase Deficiency
Intervention:
19 Recruiting Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients
Conditions: Cryopyrin-associated Periodic Syndromes (CAPS);   Familial Cold Autoinflam Syn (FCAS);   Muckle-wells Syn (MWS);   Neonatal Onset Multisystem Inflam Disease (NOMID)
Intervention:
20 Completed Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase
Conditions: Cryopyrin-associated Periodic Syndromes;   Familial Cold Autoinflammatory Syndrome;   Muckle-Wells Syndrome;   Neonatal Onset Multisystem Inflammatory Disease
Intervention: Biological: canakinumab
To Top

Previous Page Studies Shown (1-20) Next Page (21-32) Show next page of results
† Indicates status has not been verified in more than two years